Anticoagulation Monitoring with Activated Partial ThromboPlastin Time and Anti-Xa Activity in Intensive Care Unit Patients: Interest of Thrombin Generation Assay

被引:2
|
作者
Billoir, Paul [1 ]
Elie, Thomas [2 ]
Levy, Jerrold H. [3 ,4 ,5 ]
Besnier, Emmanuel [6 ]
Dureuil, Bertrand [2 ]
Veber, Benoit [2 ]
Le Cam-Duchez, Veronique [1 ]
Clavier, Thomas [2 ]
机构
[1] Normandie Univ, Rouen Univ Hosp, Vasc Hemostasis Unit, UNIROUEN,INSERM U1096, F-76000 Rouen, France
[2] Rouen Univ Hosp, Dept Anesthesiol & Crit Care, F-76000 Rouen, France
[3] Duke Univ, Dept Anesthesiol, Sch Med, Durham, NC 27710 USA
[4] Duke Univ, Dept Crit Care, Sch Med, Durham, NC 27710 USA
[5] Duke Univ, Dept Surg Cardiothorac, Sch Med, Durham, NC 27710 USA
[6] Normandie Univ, Rouen Univ Hosp, Dept Anesthesiol & Crit Care, INSERM U1096,UNIROUEN, F-76000 Rouen, France
关键词
coagulation tests; inflammation; intensive care unit; heparin; activated partial thromboplastin time; factor Xa; thrombin generation; UNFRACTIONATED HEPARIN-THERAPY; INFLAMMATORY RESPONSE; EFFICACY; APTT;
D O I
10.3390/ijms231911219
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Current guidelines recommend monitoring the anticoagulant effect of unfractionated heparin (UFH) by measuring anti-Xa activity rather than activated partial thromboplastin time (aPTT) in intensive care unit (ICU) patients. The primary objective of this study was to evaluate the correlation of aPTT, anti-Xa activity, and thrombin generation in UFH-treated ICU patients. A prospective observational pilot study was conducted in adult surgical ICU patients treated with UFH. aPTT and anti-Xa activity were monitored daily. The therapeutic target was aPTT between 50 s and 84 s, and/or anti-Xa between 0.3 and 0.7 U/mL. Correlation among aPTT, anti-Xa activity, and thrombin generation was determined by measuring endogenous thrombin potential (ETP), with the inflammatory response evaluated. C-reactive protein (CRP) was used as a marker of inflammatory response. The plasma of 107 samples from 30 ICU patients was analyzed. The correlation between aPTT and anti-Xa activity was 0.66, CI95% [0.54;0.76] (p < 0.0001). Although thrombin generation, aPTT, and anti-Xa were correlated with inflammatory responses, the correlation was higher with thrombin generation and anti-Xa activity compared to aPTT. When aPTT was in a therapeutic range, a low thrombin generation was observed but was 50% inhibited when anti-Xa was in a therapeutic range. Coagulation testing with aPTT, anti-Xa correlated with thrombin generation. A 50% decrease in thrombin generation was observed when anti-Xa was within a therapeutic range. Further work is needed to evaluate coagulation biomarker responses and clinical outcomes in specific ICU populations.
引用
收藏
页数:10
相关论文
共 44 条
  • [31] Monitoring of Unfractionated Heparin Therapy in the Intensive Care Unit Using a Point-of-Care aPTT: A Comparative, Longitudinal Observational Study with Laboratory-Based aPTT and Anti-Xa Activity Measurement
    Lardinois, Benjamin
    Hardy, Michael
    Michaux, Isabelle
    Horlait, Geoffrey
    Rotens, Thomas
    Jacqmin, Hugues
    Lessire, Sarah
    Bulpa, Pierre
    Dive, Alain
    Mullier, Francois
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (05)
  • [32] Heparin Monitoring with an Anti-Xa Protocol Compared to Activated Clotting Time in Patients on Temporary Mechanical Circulatory Support
    Feih, Joel T.
    Wallskog, Kirsten E.
    Rinka, Joseph R. G.
    Juul, Janelle J.
    Rein, Lisa
    Gaglianello, Nunzio
    Kreuziger, Lisa M. Baumann
    Joyce, David L.
    Tawil, Justin N.
    ANNALS OF PHARMACOTHERAPY, 2022, 56 (05) : 513 - 523
  • [33] Anti-Factor Xa Assay Is a Superior Correlate of Heparin Dose Than Activated Partial Thromboplastin Time or Activated Clotting Time in Pediatric Extracorporeal Membrane Oxygenation
    Liveris, Anna
    Bello, Ricardo A.
    Friedmann, Patricia
    Duffy, Melissa A.
    Manwani, Deepa
    Killinger, James S.
    Rodriquez, Daniel
    Weinstein, Samuel
    PEDIATRIC CRITICAL CARE MEDICINE, 2014, 15 (02) : E72 - E79
  • [34] Discordance in activated partial thromboplastin time and anti-factor Xa levels in COVID-19 patients on heparin therapy
    Lawlor, Matthew
    Gupta, Aakriti
    Ranard, Lauren S.
    Madhavan, Mahesh V.
    Li, Jianhua
    Eisenberger, Andrew
    Parikh, Sahil A.
    Sethi, Sanjum S.
    Masoumi, Amirali
    THROMBOSIS RESEARCH, 2021, 198 : 79 - 82
  • [35] Monitoring anticoagulation with argatroban in critically ill patients: activated partial thrombo-plastin time versus diluted thrombin time
    Keyl, Cornelius
    Lehane, Cornelius
    Zimmer, Emanuel
    Trenk, Dietmar
    THROMBOSIS AND HAEMOSTASIS, 2016, 116 (06) : 1180 - 1181
  • [36] Utility of activated partial thromboplastin time waveform analysis for identification of sepsis and overt disseminated intravascular coagulation in patients admitted to a surgical intensive care unit
    Dempfle, CEH
    Lorenz, S
    Smolinski, M
    Wurst, M
    West, S
    Houdijk, WPM
    Quintel, M
    Borggrefe, M
    CRITICAL CARE MEDICINE, 2004, 32 (02) : 520 - 524
  • [37] Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy
    McLaughlin, Kevin
    Rimsans, Jessica
    Sylvester, Katelyn W.
    Fanikos, John
    Dorfman, David M.
    Senna, Patricia
    Connors, Jean M.
    Goldhaber, Samuel Z.
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2019, 25
  • [38] Comparison of Antifactor Xa and Activated Partial Thromboplastin Time Monitoring for Heparin Dosing in Vascular Surgery Patients: A Single-Center Retrospective Study
    Rizk, Elsie
    Wilson, Allison D.
    Murillo, Michelle U.
    Putney, David R.
    THERAPEUTIC DRUG MONITORING, 2018, 40 (01) : 151 - 155
  • [40] Monitoring of Argatroban in Critically Ill Patients: A Prospective Study Comparing Activated Partial Thromboplastin Time, Point-of-Care Viscoelastic Testing with Ecarin Clotting Time and Diluted Thrombin Time to Mass Spectrometry
    Heubner, Lars
    Oertel, Reinhard
    Tiebel, Oliver
    Mehlig-Warnecke, Nicole
    Beyer-Westendorf, Jan
    Mirus, Martin
    Roessler, Martin
    Renner, Bertold
    Spieth, Peter Markus
    ANESTHESIOLOGY, 2024, 140 (02) : 261 - 271